News story from OZARKSFIRST.com on Wednesday 15 March 2023
OZARKSFIRST.com,
Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo® [nivolumab] in Traditionally Checkpoint Inhibitor Non-Responsive Tumors
Kxan,
The combination of RRx-001 + Opdivo was well tolerated PRIMETIME was a small, duration-limited pilot study with an encouraging…
Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo® [nivolumab] in Traditionally Checkpoint Inhibitor Non-Responsive Tumors
WBTW News13,
The combination of RRx-001 + Opdivo was well tolerated PRIMETIME was a small, duration-limited pilot study with an encouraging…